Johnson & Johnson Gains FDA Nod for New Immune Disorder Drug ‘Imaavy’
Healthcare leader Johnson & Johnson announced on Wednesday that the U.S. Food and Drug Administration (FDA) has granted approval for its latest drug, Imaavy, to treat individuals aged 12 and above who suffer from an immune-mediated condition known as generalized myasthenia gravis (gMG).
gMG is a chronic autoimmune disorder that impairs skeletal muscles, especially those that control movements in the eyes, mouth, throat, and limbs, often impacting a patient’s ability to perform everyday activities. Imaavy targets this issue by blocking the FcRn receptor, thereby reducing levels of IgG antibodies, which play a major role in the progression of the disease.
The FDA’s approval is based on results from a 24-week, late-stage clinical trial, which showed that the drug significantly improved patients’ ability to chew, speak, and breathe—key functions commonly disrupted by the disorder.
The newly approved drug is estimated to be effective for over 90% of gMG patients, marking a significant step in treatment accessibility. Government statistics estimate the prevalence of generalized myasthenia gravis in the U.S. at approximately 10 to 20 people per 100,000.
Imaavy will enter a competitive market alongside existing therapies from Argenx SE, AstraZeneca, and UCB. Johnson & Johnson acquired the drug through its $6.5 billion acquisition of Momenta Pharmaceuticals in 2020, a biotech firm specializing in autoimmune diseases. The company expects the drug to generate peak annual sales exceeding $5 billion.
